There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

A large cohort study finds GLP-1 receptor agonists linked to lower graft loss and mortality in kidney transplant recipients ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity ...

SAN DIEGO, March 23, 2025 — Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss. Unfortunately, shortages and high costs ...

GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin. (HealthDay News) — For patients with type 2 diabetes (T2D), glucagon-like ...

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving glucagon-like peptide 1 receptor agonists (GLP-1 RAs) within the context of ...

The issuer is solely responsible for the content of this announcement.